

# Konstantinos Tziomalos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3914592/publications.pdf>

Version: 2024-02-01

355  
papers

8,854  
citations

50276

46  
h-index

66911

78  
g-index

358  
all docs

358  
docs citations

358  
times ranked

11363  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet, The</i> , 2010, 376, 1916-1922.	13.7	594
2	The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2692-2701.	3.6	518
3	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006, 22, 873-883.	1.9	238
4	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	3.4	208
5	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. <i>Review of Diabetic Studies</i> , 2015, 12, 110-118.	1.3	169
6	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREACE Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 118-127.	0.7	158
7	Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. <i>Osteoporosis International</i> , 2009, 20, 197-207.	3.1	146
8	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	1.9	144
9	Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 140-146.	2.6	139
10	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. <i>Angiology</i> , 2007, 58, 689-697.	1.8	133
11	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	3.3	120
12	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. <i>Circulation Journal</i> , 2007, 71, 1120-1127.	1.6	119
13	Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. <i>Human Reproduction</i> , 2012, 27, 541-549.	0.9	117
14	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 509-515.	1.8	115
15	Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?. <i>Current Drug Targets</i> , 2010, 11, 122-135.	2.1	100
16	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2604-2609.	7.1	95
17	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010, 26, 713-719.	1.9	93
18	Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. <i>Human Reproduction</i> , 2016, 31, 1347-1353.	0.9	91

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. <i>World Journal of Hepatology</i> , 2012, 4, 327.	2.0	84
20	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 74-82.	2.3	75
21	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.9	72
22	Cardiovascular benefits of bariatric surgery in morbidly obese patients. <i>Obesity Reviews</i> , 2011, 12, 515-524.	6.5	72
23	Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. <i>Endocrine</i> , 2013, 44, 583-590.	2.3	72
24	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	2.1	69
25	Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	1.8	68
26	Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. <i>American Journal of Cardiology</i> , 2008, 101, 483-485.	1.6	68
27	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009, 8, 163-184.	1.9	68
28	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1215-1223.	3.4	68
29	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 638.	2.0	68
30	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	3.4	66
31	Epidemiological Survey for the Prevalence of Overweight and Abdominal Obesity in Greek Adolescents. <i>Obesity</i> , 2008, 16, 1718-1722.	3.0	66
32	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 213-221.	2.6	66
33	Malnutrition in Patients with Acute Stroke. <i>Journal of Nutrition and Metabolism</i> , 2011, 2011, 1-7.	1.8	65
34	Stress hyperglycemia and acute ischemic stroke in-hospital outcome. <i>Metabolism: Clinical and Experimental</i> , 2017, 67, 99-105.	3.4	61
35	Endocrine effects of tobacco smoking. <i>Clinical Endocrinology</i> , 2004, 61, 664-674.	2.4	60
36	The use of sibutramine in the management of obesity and related disorders: An update. <i>Vascular Health and Risk Management</i> , 2009, 5, 441.	2.3	57

#	ARTICLE	IF	CITATIONS
37	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 24-34.	0.3	55
38	Prevalence of metabolic syndrome in women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2013, 78, 586-592.	2.4	54
39	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , 2018, 16, 130-142.	1.7	54
40	Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series. <i>American Journal of Hematology</i> , 2005, 80, 197-203.	4.1	52
41	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	1.8	52
42	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011, 27, 1659-1668.	1.9	47
43	Herpes Zoster and Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2018, 9, 545-550.	2.5	47
44	Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. <i>Haematologica</i> , 2004, 89, 245-6.	3.5	47
45	Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review. <i>International Journal of Nanomedicine</i> , 2006, 1, 129-147.	6.7	46
46	Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. <i>International Journal of Clinical Practice</i> , 2008, 62, 1432-1440.	1.7	46
47	Vascular risk factors in South Asians. <i>International Journal of Cardiology</i> , 2008, 128, 5-16.	1.7	46
48	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.9	46
49	Seasonality of month of birth of patients with Gravesâ€™ and Hashimotoâ€™s diseases differ from that in the general population. <i>European Journal of Endocrinology</i> , 2007, 156, 631-636.	3.7	45
50	Treatment of congenital fibrinogen deficiency: overview and recent findings. <i>Vascular Health and Risk Management</i> , 2009, 5, 843.	2.3	45
51	Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: Beneficial or detrimental?. <i>Atherosclerosis</i> , 2010, 211, 9-14.	0.8	45
52	Statin discontinuation: an underestimated risk?. <i>Current Medical Research and Opinion</i> , 2008, 24, 3059-3062.	1.9	44
53	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. <i>Current Vascular Pharmacology</i> , 2011, 9, 647-657.	1.7	44
54	Liver iron content determination by magnetic resonance imaging. <i>World Journal of Gastroenterology</i> , 2010, 16, 1587.	3.3	42

#	ARTICLE	IF	CITATIONS
55	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. <i>Current Vascular Pharmacology</i> , 2012, 10, 162-172.	1.7	42
56	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.9	40
57	Type 2 diabetes is associated with a worse functional outcome of ischemic stroke. <i>World Journal of Diabetes</i> , 2014, 5, 939.	3.5	40
58	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1143-1160.	3.4	39
59	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <i>Annals of Medicine</i> , 2011, 43, 167-171.	3.8	39
60	Management of patients with hepatitis B in special populations. <i>World Journal of Gastroenterology</i> , 2015, 21, 1738.	3.3	39
61	Herbal medicine-related hepatotoxicity. <i>World Journal of Hepatology</i> , 2015, 7, 2189.	2.0	39
62	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	2.4	38
63	Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2012, 97, 494-500.	1.0	37
64	Prevalence and geographic variation of abdominal obesity in 7- and 9-year-old children in Greece; World Health Organization Childhood Obesity Surveillance Initiative 2010. <i>BMC Public Health</i> , 2017, 17, 126.	2.9	36
65	Atherogenesis in Renal Patients: A Model of Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2008, 6, 93-107.	1.7	36
66	Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. <i>Lipids</i> , 2007, 42, 999-1009.	1.7	35
67	Fish Oils and Vascular Disease Prevention: An Update. <i>Current Medicinal Chemistry</i> , 2007, 14, 2622-2628.	2.4	34
68	Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg <sup>+</sup> chronic hepatitis B patients: A 4-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 54-60.	2.8	34
69	The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2014, 80, 432-438.	2.4	33
70	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , 2017, 177, R145-R158.	3.7	33
71	Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. <i>Annals of Hematology</i> , 2006, 86, 23-30.	1.8	32
72	Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival. <i>Hepatology Research</i> , 2010, 40, 161-170.	3.4	32

#	ARTICLE	IF	CITATIONS
73	Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia. <i>Respirology</i> , 2010, 15, 796-803.	2.3	31
74	Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013, 168, 145-152.	3.7	31
75	Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 9039.	3.3	31
76	Health benefits and consequences of the Eastern Orthodox fasting in monks of Mount Athos: a cross-sectional study. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 743-749.	2.9	30
77	Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate. <i>Oncologist</i> , 2005, 10, 457-458.	3.7	28
78	Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 183-189.	1.6	28
79	Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease. <i>Current Pharmaceutical Design</i> , 2018, 24, 291-296.	1.9	28
80	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	2.1	27
81	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	2.1	27
82	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010, 25, 394-398.	1.8	27
83	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. <i>Angiology</i> , 2012, 63, 358-366.	1.8	27
84	Associations between nonalcoholic fatty liver disease and ischemic stroke. <i>World Journal of Hepatology</i> , 2018, 10, 474-478.	2.0	27
85	Alcohol and the Cardiovascular System: A Double-Edged Sword. <i>Current Pharmaceutical Design</i> , 2014, 20, 6276-6288.	1.9	27
86	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , 2007, 1, 8-14.	0.3	27
87	Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. <i>British Journal of Haematology</i> , 2004, 125, 91-92.	2.5	26
88	Anti-Inflammatory Effects of Fibrates: An Overview. <i>Current Medicinal Chemistry</i> , 2009, 16, 676-684.	2.4	26
89	Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. <i>International Journal of Cardiology</i> , 2009, 134, 322-329.	1.7	26
90	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010, 32, 326-331.	1.3	26

#	ARTICLE	IF	CITATIONS
91	Adipokines, Insulin Resistance and Hyperandrogenemia in Obese Patients with Polycystic Ovary Syndrome: Cross-Sectional Correlations and the Effects of Weight Loss. <i>Obesity Facts</i> , 2012, 5, 495-504.	3.4	26
92	Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2013, 29, 250-253.	1.7	26
93	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , 2018, 277, 308-313.	0.8	26
94	Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. <i>World Journal of Hepatology</i> , 2013, 5, 621.	2.0	26
95	Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels. <i>European Journal of Endocrinology</i> , 2011, 165, 63-68.	3.7	25
96	Prognostic significance of major lipids in patients with acute ischemic stroke. <i>Metabolic Brain Disease</i> , 2017, 32, 395-400.	2.9	25
97	Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 6514-6528.	3.3	25
98	Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 531-537.	3.7	24
99	Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. <i>Acta Diabetologica</i> , 2008, 45, 23-30.	2.5	24
100	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 693-700.	3.1	24
101	Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients. <i>Mediators of Inflammation</i> , 2010, 2010, 1-14.	3.0	24
102	The effect of continuous positive airway pressure therapy on blood pressure and arterial stiffness in hypertensive patients with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2014, 18, 635-640.	1.7	24
103	Diabetes mellitus and cerebrovascular disease: which are the actual data?. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 283-296.	2.3	23
104	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	1.8	23
105	No Association Observed Between Blood Pressure Variability During the Acute Phase of Ischemic Stroke and In-Hospital Outcomes. <i>American Journal of Hypertension</i> , 2016, 29, 841-846.	2.0	23
106	Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	2.3	23
107	Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. <i>World Journal of Hepatology</i> , 2020, 12, 493-505.	2.0	23
108	The Unilateral Measurement of Blood Pressure May Mask the Diagnosis or Delay the Effective Treatment of Hypertension. <i>Angiology</i> , 2005, 56, 565-569.	1.8	22

#	ARTICLE	IF	CITATIONS
109	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1593-1599.	1.9	22
110	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 723-730.	1.8	22
111	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010, 26, 839-842.	1.9	22
112	Antidiabetic treatment, stroke severity and outcome. <i>World Journal of Diabetes</i> , 2014, 5, 84.	3.5	22
113	Predictive factors that influence the course of medullary thyroid carcinoma. <i>International Journal of Clinical Oncology</i> , 2014, 19, 445-451.	2.2	22
114	Lack of an Association between Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Ischaemic Stroke. <i>European Neurology</i> , 2004, 51, 148-152.	1.4	21
115	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	1.9	21
116	The role of adipokines in ischemic stroke risk stratification. <i>International Journal of Stroke</i> , 2016, 11, 389-398.	5.9	21
117	Clinical relevance of clopidogrel-proton pump inhibitors interaction. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2015, 6, 17.	1.1	20
118	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2017, 37, 293-298.	3.0	20
119	Prevalence of overweight and abdominal obesity in Greek children 6-12 years old: Results from the National Epidemiological Survey. <i>Hippokratia</i> , 2011, 15, 48-53.	0.3	20
120	Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2012, 28, 20-24.	1.7	19
121	Elevated Diastolic But Not Systolic Blood Pressure Increases Mortality Risk in Hypertensive But Not Normotensive Patients With Acute Ischemic Stroke. <i>American Journal of Hypertension</i> , 2015, 28, 765-771.	2.0	19
122	Vascular calcification: the role of microRNAs. <i>Biomolecular Concepts</i> , 2017, 8, 119-123.	2.2	19
123	Statins for the Prevention of First or Recurrent Stroke. <i>Current Vascular Pharmacology</i> , 2008, 6, 124-133.	1.7	19
124	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	1.7	19
125	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , 2021, 345, 119-124.	1.7	19
126	Cardiac Toxicity During Rituximab Administration. <i>Leukemia and Lymphoma</i> , 2004, 45, 203-204.	1.3	18



#	ARTICLE	IF	CITATIONS
127	Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. <i>European Journal of Haematology</i> , 2007, 78, 48-51.	2.2	18
128	Lipid Lowering Agents and the Endothelium: An Update after 4 Years. <i>Current Vascular Pharmacology</i> , 2012, 10, 33-41.	1.7	18
129	The Increase in Thyroid Cancer Incidence is not only due to Papillary Microcarcinomas: a 40-year Study in 1 778 Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 397-401.	1.2	18
130	Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. <i>Human Reproduction</i> , 2013, 28, 785-793.	0.9	18
131	Obesity and Outcome of Assisted Reproduction in Patients With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2018, 9, 149.	3.5	18
132	Sodium-Glucose Co-Transporter <sup>2</sup> Inhibitors and Fracture Risk. <i>Diabetes Therapy</i> , 2020, 11, 7-14.	2.5	18
133	Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. <i>Clinical Transplantation</i> , 2005, 19, 321-326.	1.6	17
134	Reversible dilated hypocalcaemic cardiomyopathy in a patient with primary hypoparathyroidism. <i>Clinical Endocrinology</i> , 2006, 64, 717-718.	2.4	17
135	The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2013, 168, 871-877.	3.7	17
136	Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. <i>Hormones</i> , 2015, 14, 431-7.	1.9	17
137	Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. <i>Hormones</i> , 2016, 15, 35-44.	1.9	17
138	The Nutrition Health Alliance (NutriHeAl) Study: A Randomized, Controlled, Nutritional Intervention Based on Mediterranean Diet in Greek Municipalities. <i>Journal of the American College of Nutrition</i> , 2020, 39, 338-344.	1.8	17
139	Colesevelam: A New and Improved Bile Acid Sequestrant?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3115-3123.	1.9	17
140	Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity. <i>Current Vascular Pharmacology</i> , 2010, 8, 646-660.	1.7	17
141	High Density Lipoprotein Cholesterol and Statin Trials. <i>Current Medicinal Chemistry</i> , 2008, 15, 2265-2270.	2.4	16
142	Lipid-lowering agents and new onset diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1965-1970.	1.8	16
143	The Phenotypes of Polycystic Ovary Syndrome Defined by the 1990 Diagnostic Criteria Are Associated with Higher Serum Vaspin Levels than the Phenotypes Introduced by the 2003 Criteria. <i>Obesity Facts</i> , 2011, 4, 145-150.	3.4	16
144	Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome. <i>Gynecological Endocrinology</i> , 2013, 29, 926-930.	1.7	16

#	ARTICLE	IF	CITATIONS
145	Sex-specific Differences in Cardiovascular Risk Factors and Blood Pressure Control in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2014, 16, 309-312.	2.0	16
146	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 26-34.	0.3	16
147	Omega-3 fatty acids: How can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 510-517.	4.8	15
148	Brain natriuretic peptide and the athlete's heart: a pilot study. <i>International Journal of Clinical Practice</i> , 2010, 64, 511-517.	1.7	15
149	Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 463-466.	2.0	15
150	Factors associated with delayed presentation at the emergency department in patients with acute ischemic stroke. <i>Brain Injury</i> , 2019, 33, 1257-1261.	1.2	15
151	Role of lipid-lowering agents in the management of diabetic retinopathy. <i>World Journal of Diabetes</i> , 2017, 8, 1.	3.5	15
152	Lipid-lowering agents in the management of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 738.	2.0	15
153	Prevalence and severity of liver disease in patients with b thalassemia major. A single-institution fifteen-year experience. <i>Haematologica</i> , 2005, 90, 1136-8.	3.5	15
154	Management of acute bleeding in a patient with congenital afibrinogenaemia. <i>Haemophilia</i> , 2006, 12, 676-678.	2.1	14
155	Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1582-1588.	2.8	14
156	Public Awareness of Stroke Symptoms and Risk Factors and Response to Acute Stroke in Northern Greece. <i>International Journal of Stroke</i> , 2014, 9, E15-E15.	5.9	14
157	Prevalence of overweight and obesity in preschool children in Thessaloniki, Greece. <i>Hormones</i> , 2015, 14, 615-22.	1.9	14
158	Management of obesity in adolescents with polycystic ovary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 207-211.	1.8	14
159	Management of Statin-Intolerant High-Risk Patients. <i>Current Vascular Pharmacology</i> , 2010, 8, 632-637.	1.7	14
160	Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 969-972.	4.1	13
161	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. <i>Current Vascular Pharmacology</i> , 2010, 8, 792-803.	1.7	13
162	Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. <i>Hormones</i> , 2013, 12, 559-566.	1.9	13

#	ARTICLE	IF	CITATIONS
163	Increased augmentation index is paradoxically associated with lower in-hospital mortality in patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2014, 236, 150-153.	0.8	13
164	Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2015, 243, 65-70.	0.8	13
165	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2018, 16, 214-218.	1.7	13
166	Ductal plate malformation and congenital hepatic fibrosis Clinical and histological findings in four patients. <i>Hepatology Research</i> , 2006, 35, 147-150.	3.4	12
167	Short-term Administration of Orlistat Reduced Daytime Triglyceridemia in Obese Women With the Metabolic Syndrome. <i>Angiology</i> , 2007, 58, 26-33.	1.8	12
168	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 809-820.	3.4	12
169	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 16-17.	2.8	12
170	Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]. <i>Current Vascular Pharmacology</i> , 2009, 7, 264-266.	1.7	12
171	The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. <i>Hormones</i> , 2013, 12, 192-200.	1.9	12
172	Novel treatment options for the management of heterozygous familial hypercholesterolemia. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1375-1381.	3.1	12
173	Masked hypertensives: A disguised arterial stiffness population. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1473-1480.	2.0	12
174	Pegylated IFN- $\alpha$ 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2006, 12, 2417.	3.3	12
175	Skin Involvement in Hodgkin's Disease. <i>Cancer Investigation</i> , 2006, 24, 401-403.	1.3	11
176	DRY COUGH AS FIRST MANIFESTATION OF GIANT-CELL ARTERITIS. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1957-1958.	2.6	11
177	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	1.8	11
178	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. <i>Current Pharmaceutical Design</i> , 2007, 13, 229-239.	1.9	11
179	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1931-1940.	1.9	11
180	Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 85-89.	0.3	11

#	ARTICLE	IF	CITATIONS
181	Can Capsule Endoscopy Be Used as a Diagnostic Tool in the Evaluation of Nonbleeding Indications in Daily Clinical Practice? A Prospective Study. <i>Medical Principles and Practice</i> , 2011, 20, 362-367.	2.4	11
182	Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome. <i>Hormones</i> , 2018, 16, 373-380.	1.9	11
183	Treatment with Mannitol is Associated with Increased Risk for In-Hospital Mortality in Patients with Acute Ischemic Stroke and Cerebral Edema. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 397-403.	2.2	11
184	Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 679-689.	2.0	11
185	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	5.9	11
186	Predictive value of the ankle brachial index in patients with acute ischemic stroke. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 55-61.	1.4	11
187	Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003, 123, 958-958.	2.5	10
188	Nitric Oxide and Cardiobiology—Methods for Intact Hearts and Isolated Myocytes. <i>Methods in Enzymology</i> , 2008, 441, 369-392.	1.0	10
189	Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. <i>Angiology</i> , 2009, 60, 74-81.	1.8	10
190	Combined Chelation Therapy with Deferoxamine and Deferiprone in $\beta^2$ -Thalassemia Major: Compliance and Opinions of Young Thalassaemic Patients. <i>Hemoglobin</i> , 2014, 38, 111-114.	0.8	10
191	Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome. <i>Minerva Endocrinology</i> , 2017, 42, 122-131.	1.1	10
192	Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. <i>Regenerative Medicine</i> , 2018, 13, 277-281.	1.7	10
193	A Comparative Assessment of Cardiovascular Autonomic Reflex Testing and Cardiac <sup>123</sup> I-Metaiodobenzylguanidine Imaging in Patients with Type 1 Diabetes Mellitus without Complications or Cardiovascular Risk Factors. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	1.5	10
194	Impaired antioxidative activity of high-density lipoprotein is associated with more severe acute ischemic stroke. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 49-52.	3.4	10
195	Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia — spotlight on volanesorsen. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 389-394.	4.1	10
196	Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 189-191.	3.0	10
197	Secondary Hypertension: Novel Insights. <i>Current Hypertension Reviews</i> , 2020, 16, 11-11.	0.9	10
198	Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome. <i>Hormones</i> , 2015, 15, 35-44.	1.9	10

#	ARTICLE	IF	CITATIONS
199	Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2013, 4, 4.	1.1	10
200	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , 2011, 6, 1067-1075.	0.9	9
201	Effects of Different Classes of Antihypertensive Agents on the Outcome of Acute Ischemic Stroke. <i>Journal of Clinical Hypertension</i> , 2015, 17, 275-280.	2.0	9
202	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , 2017, 16, 306-312.	1.9	9
203	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. <i>Current Pharmaceutical Design</i> , 2014, 20, 6350-6357.	1.9	9
204	Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure. <i>Current Pharmaceutical Design</i> , 2014, 20, 6306-6313.	1.9	9
205	New guidelines for the diagnosis and management of pulmonary embolism: Key changes. <i>World Journal of Cardiology</i> , 2020, 12, 161-166.	1.5	9
206	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>Hippokratia</i> , 2015, 19, 195-9.	0.3	9
207	Protein-losing enteropathy as the principal manifestation of constrictive pericarditis. <i>Journal of General Internal Medicine</i> , 2005, 20, C5-C7.	2.6	8
208	Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 913-915.	0.5	8
209	Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 445-449.	4.1	8
210	JUPITER: major implications for vascular risk assessment. <i>Current Medical Research and Opinion</i> , 2009, 25, 133-137.	1.9	8
211	Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2013, 4, 14.	3.5	8
212	Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene. <i>Brain Injury</i> , 2015, 29, 658-660.	1.2	8
213	High-density lipoprotein: quantity or quality?. <i>Journal of Thoracic Disease</i> , 2016, 8, 2975-2977.	1.4	8
214	Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 336-342.	2.1	8
215	Major Adipokines and the $\alpha$ -420&gt;G Resistin Gene Polymorphism as Predictors of Acute Ischemic Stroke Severity and In-Hospital Outcome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 963-970.	1.6	8
216	Healthcare reform in China: challenges and opportunities. <i>Current Medical Research and Opinion</i> , 2018, 34, 821-823.	1.9	8

#	ARTICLE	IF	CITATIONS
217	Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2013, 19, 3766-3772.	1.9	8
218	Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3664-3668.	3.3	8
219	Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11196.	4.1	8
220	Elevated Levels of Serum Vascular Endothelial Growth Factor in Patients with Polycythaemia vera. <i>Acta Haematologica</i> , 2003, 110, 16-19.	1.4	7
221	CORONA, Statins, and Heart Failure: Who Lost the Crown?. <i>Angiology</i> , 2008, 59, 5-8.	1.8	7
222	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	1.9	7
223	To switch (statins) or not to switch? That is the question. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2943-2946.	1.8	7
224	Plasma Von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. <i>Hormones</i> , 2012, 11, 77-85.	1.9	7
225	Non-Alcoholic Fatty Liver Disease in Patients with HIV Infection. <i>AIDS Reviews</i> , 2018, 20, 171-173.	1.0	7
226	Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease. <i>Current Vascular Pharmacology</i> , 2015, 13, 649-657.	1.7	7
227	Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2010, 2, 91.	2.0	7
228	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016, 15, 8-14.	1.9	7
229	Lack of an association between angiotensin converting enzyme gene polymorphism and peripheral arterial occlusive disease. <i>Vascular Medicine</i> , 2004, 9, 189-192.	1.5	6
230	Mitral valve reconstruction in a compound heterozygote for sickle cell anemia and hemoglobin Lepore. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 932-933.	0.8	6
231	Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1437-1440.	1.8	6
232	Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]. <i>Current Vascular Pharmacology</i> , 2008, 6, 81-83.	1.7	6
233	Effect of Prior Treatment with Different Statins on Stroke Severity and Functional Outcome at Discharge in Patients with Acute Ischemic Stroke. <i>International Journal of Stroke</i> , 2013, 8, E49-E49.	5.9	6
234	Prophylactic antibiotic treatment in severe acute ischemic stroke: the Antimicrobial chemoprophylaxis for Ischemic STroK E In MaceDonlaêThrace Study (ARISTEIDIS). <i>Internal and Emergency Medicine</i> , 2016, 11, 953-958.	2.0	6

#	ARTICLE	IF	CITATIONS
235	Nonalcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome. <i>European Journal of Neurology</i> , 2018, 25, 610-611.	3.3	6
236	Left ventricular hypertrophy assessed by electrocardiogram is associated with more severe stroke and with higher in-hospital mortality in patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2018, 274, 206-211.	0.8	6
237	Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review. <i>Diabetes Therapy</i> , 2019, 10, 429-435.	2.5	6
238	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020, 19, 114.	3.0	6
239	Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2014, 20, 6106-6113.	1.9	6
240	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , 2017, 23, 1477-1483.	1.9	6
241	Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 134-138.	0.7	6
242	Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 226-230.	0.3	6
243	The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease. <i>Hippokratia</i> , 2016, 20, 259-263.	0.3	6
244	Is propofol the optimal sedative in gastrointestinal endoscopy?. <i>Acta Gastro-Enterologica Belgica</i> , 2018, 81, 520-524.	1.0	6
245	Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1777-1779.	4.1	5
246	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 57-68.	0.3	5
247	Atherosclerotic Renal Artery Stenosis: Medical Therapy Alone or in Combination with Revascularization?. <i>Angiology</i> , 2009, 60, 397-402.	1.8	5
248	Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome. <i>Blood Pressure</i> , 2013, 22, 307-311.	1.5	5
249	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1059-1066.	1.5	5
250	Obesity in patients with HIV infection: epidemiology, consequences and treatment options. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 395-402.	2.4	5
251	Effects of obesity on the outcome of pneumonia. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 315-320.	2.4	5
252	The Role of Finerenone in the Management of Diabetic Nephropathy. <i>Diabetes Therapy</i> , 2021, 12, 1791-1797.	2.5	5

#	ARTICLE	IF	CITATIONS
253	Is There a Role for Continuous Positive Airway Pressure Treatment in the Management of Obstructive Sleep Apnea-related Hypertension?. <i>Current Hypertension Reviews</i> , 2018, 13, 89-92.	0.9	5
254	Soluble receptor for advanced glycation end products in male infertility. <i>Hippokratia</i> , 2017, 21, 19-24.	0.3	5
255	Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population. <i>Journal of Personalized Medicine</i> , 2022, 12, 1139.	2.5	5
256	Paralysis as first manifestation of primary aldosteronism. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2418-2419.	0.7	4
257	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	1.9	4
258	Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. <i>Cerebrovascular Diseases</i> , 2016, 41, 226-232.	1.7	4
259	Barriers to insulin treatment in patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 233-234.	1.8	4
260	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	3.5	4
261	Treatment of heterozygous familial hypercholesterolemia: what does the future hold?. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1229-1234.	3.1	4
262	Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 4165-4174.	2.9	4
263	An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1799-1803.	1.8	4
264	Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome. <i>Hormones</i> , 2020, 19, 565-571.	1.9	4
265	Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring. <i>Journal of Clinical Medicine</i> , 2021, 10, 1982.	2.4	4
266	Treatment of idiopathic retroperitoneal fibrosis with combined administration of corticosteroids and tamoxifen. <i>Clinical Nephrology</i> , 2004, 62, 74-76.	0.7	4
267	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6522-6526.	3.3	4
268	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. <i>Endocrine</i> , 2022, 76, 324-330.	2.3	4
269	Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease. <i>Annals of Oncology</i> , 2005, 16, 514-515.	1.2	3
270	Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]. <i>Current Vascular Pharmacology</i> , 2010, 8, 1-4.	1.7	3



#	ARTICLE	IF	CITATIONS
271	Impaired Fasting Glucose in Hypertensive Patients: Prevalence and Cross-Sectional Analysis of Associations with Cardiovascular Disease. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 475-480.	4.4	3
272	Uterine Volume and Endometrial Thickness in the Early Follicular Phase in Patients with Polycystic Ovary Syndrome. <i>Endocrine Practice</i> , 2014, 20, 540-547.	2.1	3
273	Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs. <i>Current Vascular Pharmacology</i> , 2016, 14, 208-210.	1.7	3
274	Impaired kidney function evaluated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is associated with more severe acute ischemic stroke. <i>Vascular Medicine</i> , 2017, 22, 432-434.	1.5	3
275	Fixed-dose combinations: A valuable tool to improve adherence to antihypertensive treatment. <i>Journal of Clinical Hypertension</i> , 2018, 20, 908-909.	2.0	3
276	Ambulatory arterial stiffness evaluation: A step forward in the management of hypertension. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1169-1170.	2.0	3
277	Effects of major adipokines and the $\delta 420 \text{ C} \rightarrow \text{G}$ resistin gene polymorphism on the long-term outcome of patients with acute ischemic stroke. <i>International Journal of Neuroscience</i> , 2019, 129, 978-985.	1.6	3
278	Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?. <i>Annals of Gastroenterology</i> , 2021, 34, 476-486.	0.6	3
279	The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. <i>Current Pharmaceutical Design</i> , 2017, 23, 1495-1499.	1.9	3
280	The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. <i>Folia Medica</i> , 2018, 60, 512-520.	0.5	3
281	A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. <i>World Journal of Gastroenterology</i> , 2006, 12, 818.	3.3	3
282	Role of ceniciviroc in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 5415-5417.	3.3	3
283	Combination treatment in HBeAg-negative chronic hepatitis B. <i>World Journal of Hepatology</i> , 2009, 1, 43.	2.0	3
284	Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. <i>Hippokratia</i> , 2013, 17, 246-51.	0.3	3
285	Buflomedil: potential new indications for an old agent. <i>International Angiology</i> , 2009, 28, 170-4.	0.9	3
286	Clinical controversies in lipid management. <i>Panminerva Medica</i> , 2015, 57, 65-70.	0.8	3
287	The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke. <i>Diseases (Basel)</i> , 2021, 9, 1078.	2.5	3
288	Endoscopic variceal ligation for portal hypertension due to myelofibrosis with myeloid metaplasia. <i>European Journal of Haematology</i> , 2004, 72, 379-380.	2.2	2

#	ARTICLE	IF	CITATIONS
289	Metabolic syndrome in patients with the polycystic ovary syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 559-568.	2.4	2
290	Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Design, 2014, 20, 6215-6219.	1.9	2
291	Arterial stiffness correlates with the severity of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2017, 263, e197.	0.8	2
292	Obesity is an independent risk factor for pneumonia in patients admitted with acute ischemic stroke. <i>Atherosclerosis</i> , 2018, 275, e75.	0.8	2
293	Greek gynecology healthcare professionals towards quality management systems. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 164-175.	0.9	2
294	Prevalence of non-coronary heart disease in patients with familial hypercholesterolemia: An analysis from the HELLAS-FH. <i>Atherosclerosis</i> , 2021, 331, e185-e186.	0.8	2
295	Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1277-1282.	1.6	2
296	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , 2017, 13, 200-204.	1.9	2
297	The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmaceutical Design</i> , 2019, 24, 5525-5527.	1.9	2
298	The association of in vitro fertilization/intracytoplasmic sperm injection results with anxiety levels and stress biomarkers: An observational, case-control study. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 51, 102254.	1.3	2
299	Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?. <i>World Journal of Diabetes</i> , 2020, 11, 370-373.	3.5	2
300	Persistent effect of zoledronic acid in Paget's disease. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 464-6.	0.8	2
301	Focal nodular hyperplasia of the liver in a patient with primary aldosteronism. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 480-481.	2.8	1
302	Gardnerâ€Diamond Syndrome. <i>Journal of Dermatology</i> , 2004, 31, 587-588.	1.2	1
303	Raised liver enzymes in patients taking statins â€ Authors' reply. <i>Lancet, The</i> , 2011, 377, 1075-1076.	13.7	1
304	Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management. <i>Current Vascular Pharmacology</i> , 2011, 9, 465-470.	1.7	1
305	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 185-189.	1.0	1
306	Adherence to antihyperglycemic treatment: a work in progress. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1579-1580.	1.8	1

#	ARTICLE	IF	CITATIONS
307	Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 117, 311-312.	1.6	1
308	Effect of antihypertensive treatment on the long-term outcome of patients discharged after acute ischemic stroke. <i>Clinical and Experimental Hypertension</i> , 2017, 39, 246-250.	1.3	1
309	Blood Pressure Variability: Does it Predict the Outcome of Acute Ischemic Stroke?. <i>American Journal of Hypertension</i> , 2017, 30, 476-477.	2.0	1
310	Effects of major adipokines on the long-term outcome of patients with acute ischemic stroke. <i>Atherosclerosis</i> , 2017, 263, e149.	0.8	1
311	Novel Insights in the Management of Dyslipidemia in Patients With HIV Infection. <i>Current Pharmacology Reports</i> , 2018, 4, 112-119.	3.0	1
312	Gynecology healthcare professionals towards safety procedures in operation rooms aiming to enhanced quality of medical services in Greece. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 805-817.	0.9	1
313	What special considerations must be made for the pharmacotherapeutic management of heterozygous familial hypercholesterolemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1175-1180.	1.8	1
314	Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 270-272.	2.0	1
315	Heterozygous familial hypercholesterolemia: prevalence and control rates. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 175-179.	2.4	1
316	Using Serum Biomarkers for Identifying Unstable Carotid Plaque: Update of Current Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1899-1903.	1.9	1
317	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. <i>Current Pharmaceutical Design</i> , 2021, 27, 2537-2544.	1.9	1
318	Blood pressure variability: Prognostic implications in low-risk subjects. <i>Journal of Clinical Hypertension</i> , 2021, 23, 813-814.	2.0	1
319	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. <i>World Journal of Diabetes</i> , 2020, 11, 150-154.	3.5	1
320	Management of type 2 diabetes mellitus in youth. <i>World Journal of Diabetes</i> , 2012, 3, 182.	3.5	1
321	Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome. <i>Current Pharmaceutical Design</i> , 2016, 22, 5547-5553.	1.9	1
322	Unresolved issues in lipid-lowering treatment. <i>Panminerva Medica</i> , 2016, 58, 191-5.	0.8	1
323	Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C. <i>Gastroenterology &amp; Hepatology</i> , 2023, 46, 58-66.	0.5	1
324	Hereditary spherocytosis uncovered in adulthood due to concomitant lead poisoning. <i>Annals of Hematology</i> , 2005, 84, 131-132.	1.8	0

#	ARTICLE	IF	CITATIONS
325	Multifocal mucosa-associated lymphoid tissue lymphoma presenting as lower-GI bleeding. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 465-467.	1.0	0
326	P4.62 PROGNOSTIC VALUE OF ARTERIAL STIFFNESS INDICES IN PATIENTS WITH ACUTE ISCHEMIC STROKE. <i>Artery Research</i> , 2012, 6, 200.	0.6	0
327	The prognostic significance of nonalcoholic fatty liver disease in patients with acute ischemic stroke. <i>European Journal of Internal Medicine</i> , 2013, 24, e48.	2.2	0
328	Are antibodies against PCSK9 the statins of the 21st century?. <i>Clinical Lipidology</i> , 2014, 9, 141-144.	0.4	0
329	Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A. <i>Current Vascular Pharmacology</i> , 2015, 13, 696-698.	1.7	0
330	Cardiovascular Risk in Middle East Populations. <i>Angiology</i> , 2015, 66, 801-802.	1.8	0
331	Response to "Brachial Systolic Blood Pressure Fails to Predict Short-Term Outcome in Patients With Acute Ischemic Stroke: What About Central Systolic Pressure?" <i>American Journal of Hypertension</i> , 2015, 28, 1181-1181.	2.0	0
332	The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 102.	2.5	0
333	P736 Impaired antioxidant activity of high-density lipoprotein is associated with more severe ischemic stroke. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
334	The challenge of gender-specific pharmacotherapy for stroke prevention and treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1849-1851.	1.8	0
335	Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 1713-1715.	1.9	0
336	P5321 The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
337	A Comparison Of The Predictive Ability Of Pooled Cohort Equation, Score Equation And D:A:D Study Equation In People Living With Hiv. <i>Atherosclerosis</i> , 2019, 287, e113.	0.8	0
338	Children With Familial Hypercholesterolemia: Cardiometabolic Profile Data From The Hellas-Fh Registry. <i>Atherosclerosis</i> , 2019, 287, e210.	0.8	0
339	Nonalcoholic Fatty Liver Disease: Current Concepts. <i>Current Pharmaceutical Design</i> , 2019, 24, 4564-4565.	1.9	0
340	The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. <i>Current Pharmacology Reports</i> , 2019, 5, 210-213.	3.0	0
341	Cardiovascular risk prediction in patients with HIV infection. <i>Future Virology</i> , 2019, 14, 711-714.	1.8	0
342	Effect Of High And Low Dose Of Rosuvastatin On Fatty Liver Disease And 24-Hour Arterial Stiffness In Patients With Non-Alcoholic Fatty Liver Disease. <i>Atherosclerosis</i> , 2019, 287, e203.	0.8	0

#	ARTICLE	IF	CITATIONS
343	P5324Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
344	Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e210-e211.	0.8	0
345	Coexistence of cardiovascular risk factors in patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , 2020, 315, e211.	0.8	0
346	P1270INCREASED SCLEROSTIN, BUT NOT DKK-1 PROTEIN, IS ASSOCIATED WITH ELEVATED PULSE WAVE VELOCITY IN HEMODIALYSIS SUBJECTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
347	Hepatic fibrosis is associated with higher in-hospital mortality in patients admitted with acute ischemic stroke. <i>Atherosclerosis</i> , 2021, 331, e233.	0.8	0
348	Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2261-2266.	1.8	0
349	Dilemmas and Treatment Options for Medical Conditions in the Woman's Life Span. <i>Current Pharmaceutical Design</i> , 2021, 27, 3753-3753.	1.9	0
350	Can We Move Forward After ADVANCE?. <i>Vascular Disease Prevention</i> , 2008, 5, 72-74.	0.2	0
351	Role of Metalloproteinases in the Pathogenesis of Unexpected Poor Ovarian Response with a Possible Genetic Predisposition. <i>International Journal of Infertility and Fetal Medicine</i> , 2017, 8, 5-11.	0.1	0
352	Cancer prevention in patients with human immunodeficiency virus infection. <i>World Journal of Clinical Oncology</i> , 2018, 9, 71-73.	2.3	0
353	Novel insights in the prevention of perinatal transmission of hepatitis B. <i>World Journal of Hepatology</i> , 2018, 10, 795-798.	2.0	0
354	Should all Hypertensive Patients be Screened for Primary Aldosteronism?. <i>Current Hypertension Reviews</i> , 2019, 15, 54-56.	0.9	0
355	Cardiovascular diseases in pregnancy. <i>American Journal of Cardiovascular Disease</i> , 2012, 2, 96-101.	0.5	0